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Abstract 
This clinical vignette illustrates how our therapeutic approaches to early stages of multiple myeloma have changed over the past 
decade with novel therapies reducing disease and preventing disease progression.  Recent paradigms of multiple myeloma 
describe the disease as a spectrum of clinical stages, including asymptomatic ‘smoldering’ states that progress to symptomatic 
states.  The average 5-year survival rate of patients with multiple myeloma diagnosed between 1996 and 2004 according to 
surveillance epidemiology and end results (SEER) data is 35.9%.  Here, we describe the use of novel therapeutic agents 
including bortezomib, lenalidomide, bisphosphonates, Doxil/Caelyx, and dexamethasone, and their success in affecting the 
course of disease.  Multiple trials have shown an increased benefit of these newer agents over prior multiple myeloma treatment 
regimens.  At 13 years and 8 months from diagnosis, our patient is doing well, and thus is a model of how long-term control of 
multiple myeloma prolongs survival. 
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Case 
A 59-year-old woman was found to have increased total protein 
on routine blood tests in February 1996.  Serum protein 
electrophoresis revealed an IgA spike of 2.2 g/dl, and bone 
marrow biopsy showed 20%-30% plasma cells, confirming the 
diagnosis of multiple myeloma (because of lack of symptoms, 
Kyle and colleagues would classify it as ‘smoldering’ – see in 
the following).  According to the earliest blood work available, 
the patient’s haemoglobin was 11.5 in December 1998.  At the 
outset and in subsequent evaluations she never went on to 
demonstrate lytic bone lesions (but did eventually manifest a 
compression fracture of T11); likewise there was no proteinuria, 
and chemistries including calcium and creatinine were normal.  
Medications that the patient was taking at the time were 
enalapril, hydralazine, carvedilol, and levothyroxine, 
respectively.  The patient was started on melphalan and 
dexamethasone, in large part because of concerns with the 
amount of paraprotein.  Despite this therapy, however, her IgA 
rose further from greater than 2-4.1 g/dl in 1999; she 
subsequently underwent treatment with four cycles of 
carmustine, doxorubicin, and dexamethasone.  In response to 
this regimen, her IgA fell to 1.9 g/dl.  However, the course was 
complicated by febrile neutropenia requiring two hospitalizations 
and intravenous antibiotics.  In early 2000, she was started on 
intravenous bisphosphonates (pamidronate) by her current 
oncologist (FM), and as her IgA again rose to 2.9 g/dl, she was 
started on pegylated liposomal doxorubicin (Doxil/Caelyx) 40 
mg/m
2 every 4 weeks.  Her IgA declined and remained stable at 
1.9 g/dl for nearly 3 years (Figure 1). 
When the IgA again rose to 2.8 g/dl at the end of 2003 in spite 
of 4 months of thalidomide added to the regimen, she was 
begun on bortezomib that had just become available.  The 
addition of bortezomib 1.3 mg/m
3 days 1, 4, 8, 11 every three 
weeks to Doxil/Caelyx and pamidronate brought the IgA 
promptly down to 1.5 g/dl.  However, the patient experienced 
symptoms of congestive heart failure (venous distension, 
fatigue, and cardiac enlargement by X-ray).  The left ventricular 
ejection fraction on transthoracic echocardiography was 30%, 
and Doxil/Caelyx was discontinued (Figure 1).  Bortezomib was 
reduced to 2.2 mg on days 1, 4, 8 every 21 days in accordance 
to patient wishes.  On bortezomib, the patient’s IgA remained 
stable at 1.8 g/dl for about two years until rising slowly 
accompanied by an increase in serum creatinine to above the 
normal range.  These events prompted the addition of the newly 
approved lenalidomide (in doses no higher than 10 mg daily x 
10 days, because of her prior intolerance to thalidomide) to 
bortezomib in May 2006.  The patient’s IgA has subsequently 
been stable at 2.2 g/dl in June 2008 on this combination, and 
her creatinine has returned towards normal (Figure 2).  She has 
also been continued on zoledronate every 3 months.  She is 
clinically well except for having some progressive inability to 
walk up stairs and dyspnoea on exertion in spite of a maximal 
regimen for cardiac pre-load and after-load reduction.   
Bortezomib has been attenuated to treatment on days 1 and 4 
every 4 weeks, in part, because of the development of mild but 
recurrent gastrointestinal symptoms and recent complaints of 
grade 1 sensory neuropathy. 
 
Discussion 
Multiple myeloma is a malignant proliferation of plasma cells 
and accounts for 1% of all malignancies.  This disease affects 
one  to five individuals per 100,000 [1]. The average 5-year 
survival rate of patients with multiple myeloma that was 
diagnosed between 1996 and 2004 according to surveillance 
epidemiology and end results (SEER) data is 35.9% [2]. 
Survival for patients with symptomatic multiple myeloma is 3-4 
years.   
The above clinical vignette illustrates advances made in multiple 
myeloma treatment and understanding over the past 15 years 
and their effects on improving outcomes and survival in earlier 
stages of myeloma as shown in the aforementioned patient.  In 
current paradigms of multiple myeloma, multiple myeloma 
arises from an asymptomatic premalignant disorder that is 
known as monoclonal gammopathy of unknown significant 
(MGUS).  MGUS first progresses to ‘smoldering’ multiple 
myeloma, an asymptomatic state, and then to symptomatic 
multiple myeloma.  The International Myeloma Working Group 
defines smoldering myeloma as a disorder in which the patient 
has a serum monoclonal protein level of 3 g/dl or more or a 
proportion of plasma cells in the bone marrow of 10% or more 
with no end-organ damage (hypercalcemia, renal insufficiency, 
anaemia, bone lesions, recurrent bacterial infections, etc.) [3].     
Patients with smoldering myeloma have a 73% chance in 15 
years in progressing to multiple myeloma, and this risk is 
greatest in the first few years after diagnosis [4]. The median 
time to progression to symptomatic disease is 1-2 years [5].  
Southwest Oncology Group sequential studies of treatments for 
symptomatic multiple myeloma from 1970s well into the 1990s 
showed little progress with the addition of multiple
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Figure 1: LVEF over time.  A normal LVEF by echocardiography was documented in April 2000 after two cycles of free doxorubicin and at the 
onset of Doxil/Caelyx.  The patient had no signs and symptoms of cardiac disease until bortezomib was added to Doxil/Caelyx (February 2004) 
and simultaneously with a marked drop in IgA.  The Doxil/Caelyx was discontinued and after medical management of hypertension and heart 
failure, the LVEF rose towards baseline in January 2006. 
 
 
Figure 2: IgA and total protein over time in relation to treatments underwent by patient.  The patient’s IgA has been stable between 2000 and 
3000 mg/dl since the addition of bortezomib in 2003.  The total protein has been stable between 8.0 and 9.0 g/dl with treatment.  Treatments are 
starred as following: *1 = melphalan and dexamethasone; *2 = carmustine and doxorubicin; *3 = pegylated liposomal doxorubicin; *4 = 
bortezomib; *5 = lenalidomide added to continued bortezomib. 
chemotherapeutic drugs over what could be achieved with 
alkylating drugs such as melphalan in combination with 
glucocorticoids [6,7]. However, the introduction of 
bisphosphonates and thalidomide heralded changes in outcome
wrought outside the traditional cytotoxic drugs [8,9]. These 
changes were followed by the dramatic activity of a proteasome 
inhibitor, bortezomib, and later by a better tolerated 
immunomodulatory drug, lenalidomide, to replace thalidomide 
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[10,11]. Understanding of the molecular biology of the malignant 
plasma cell and its relationship to the bone marrow stroma is 
leading to several additional advances in treatment strategies.  
Although prior recommendations suggested close follow-up for 
patients with smoldering myeloma, new trials have been 
studying benefits in using new therapies for this group of 
patients in an effort to improve survival or even prevent 
progression to symptomatic disease.  The recommendation for 
observation of asymptomatic patients is based on trials of 
asymptomatic patients randomized to observation versus 
melphalan and prednisone therapy.  These studies showed no 
differences in survival.  However, new agents may change this 
paradigm [12,13]. Investigators have been studying the use of 
bisphosphonates, thalidomide, lenalidomide, and bortezomib in 
the treatment of smoldering myeloma.  In the context of the 
current patient, bortezomib, lenalidomide, bisphosphonates, 
Doxil/Caelyx, and dexamethasone appeared to affect the 
course of the disease more than the initial chemotherapy.  
Thalidomide, an anti-angiogenic agent, may delay progression 
to active disease.  Early trials with thalidomide were based on 
the observation of increased angiogenesis in multiple myeloma 
[14]. Rajkumar et al. showed that thalidomide is effective in 
treating early stage multiple myeloma [15]. One trial of 
thalidomide in early stage multiple myeloma found a 63% 2-year 
progression-free survival.  In this study, 34% of study 
participants had a partial response to thalidomide therapy [16].  
Another study found a median survival of more than 5 years 
with thalidomide therapy for smoldering multiple myeloma [17]. 
Lenalidomide is a third generation immunomodulatory drug that 
is a thalidomide analogue but with improved side effects.   
Although studies have shown high clinical responses and 
survival benefits of lenalidomide in newly diagnosed, untreated 
myeloma, further studies need to be performed to assess its 
effectiveness in asymptomatic myeloma [18,19]. In patients with 
newly diagnosed multiple myeloma, initial treatment with a 
regimen of lenalidomide, melphalan, and prednisone had a 
100% survival at 1 year, and an initial treatment combination of 
dexamethasone and lenalidomide showed a 3-year survival of 
88% [20,21]. These overall survival results are significantly 
better than that for the prior gold standard regimen of melphalan 
and prednisone. 
Bortezomib is the first proteasome inhibitor to be used in clinical 
treatment and represents a novel approach to cancer therapy.  
By inhibiting the ubiquitin-proteasome signalling pathway, it 
leads to cell death.  Although bortezomib was first studied and 
found to be effective in patients with refractory or relapsed 
myeloma, it has also been shown to be effective in previously 
untreated patients [22]. The Phase III Vista trial showed that in 
elderly patients with previously untreated myeloma not eligible 
for transplantation, the addition of bortezomib to the previous 
gold standard of melphalan and prednisone improved both 
length of time before disease progression and overall survival.  
The complete response rate of bortezomib, melphalan, and 
prednisone was 30%, while it was 4% in the control group 
receiving melphalan and prednisone.  The median time to 
progression was 24 months in the group with bortezomib, while 
it was 16.6 months in the control group [24-25]. More recently, 
the combination of bortezomib with Doxil/Caelyx was found to 
be effective and gained FDA approval [26,27]. This combination 
has been very well tolerated, although in our patient, it was 
associated with perhaps coincidental acute cardiac 
decompensation.  The aetiology of our patient’s cardiac disease 
is not clear, and is associated with hypertension, unlike 
anthracycline cardiomyopathy [28]. 
Bisphosphonates are now an integral part of the therapeutic 
armamentarium, not only in preventing the progression of bone 
disease and pathologic fractures, but perhaps also working via 
the microenvironment to decrease the proliferation and 
invasiveness of the myeloma cells.  Better supportive care and 
prevention of complications associated with multiple myeloma 
such as hypercalcemia, renal failure, and bone lesions have 
also contributed to improved survival and quality of life.  New 
therapies as described above may delay or even prevent the 
progression of smoldering multiple myeloma to symptomatic 
states.  Advances in both clinical care and therapeutic agents 
are allowing patients to live longer with this disease without 
compromising quality of life in a major way.  The course in this 
particular patient is illustrative of how long term control of the 
disease is achievable by the introduction of a number of 
measures associated with an excellent therapeutic index. 
Acknowledgements: Stuart Dickerman, MD, Andrea Downey, 
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